Saturday 17 October 2026
Export MRM’s income statement to Excel — free account
MEDIROM Healthcare Technologies Inc. Unsponsored ADR
MRM Consumer Cyclical Personal Services
MEDIROM Healthcare Technologies Inc. Unsponsored ADR’s revenue for fiscal 2024 (year ended December 2024) was $54.8 million, up 13.0% from fiscal 2023.
0.36
0.02
−5.26%
Follow MRM
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | 6 | 2 | 6 |
P/S ratio |
— | 0.00 | 0.00 | 0.00 | 0.30 | 0.23 | 0.29 | 0.05 |
Altman Z-Score |
— | — | — | 0.33 | (0.04) | 0.57 | 0.86 | 0.91 |
Altman Z″-Score (non-manufacturers) |
— | (2.27) | — | (2.40) | (4.18) | (2.39) | (2.04) | (0.97) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | (2.66) | (1.71) | (1.97) | (1.22) |
P/Operating CF |
— | (17.55) | (17.55) | (16.73) | (7.03) | (5.40) | (6.67) | (1.20) |
P/B ratio |
— | 41.74 | 41.74 | 12.54 | 0.00 | 0.00 | 15.05 | 0.64 |
Price to Tangible BV |
— | 0.00 | 0.00 | 25.36 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 0.00 | 0.00 | 0.49 | 0.41 | 0.53 | 0.18 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.00 | 0.00 | 0.00 | (2.59) | (2.09) | (2.60) | (0.11) |
EV/FCF |
— | 0.00 | 0.00 | 0.00 | (2.59) | (1.83) | (2.28) | (0.11) |
Quick Ratio |
— | 0.37 | 0.58 | 0.77 | 0.39 | 0.54 | 0.38 | 0.56 |
Current Ratio |
— | 0.40 | 0.61 | 0.79 | 0.43 | 0.65 | 0.49 | 0.65 |
Net Debt/EBITDA |
— | 16.56 | 14.52 | (0.63) | (4.76) | 6.51 | (19.81) | 5.67 |
Debt/Assets |
0.00% | 63.00% | 0.00% | 33.32% | 35.42% | 36.48% | 42.13% | 23.20% |
Debt/Equity |
— | (24.23) | 3.94 | 3.87 | (9.78) | (41.46) | 13.36 | 1.90 |
Asset Turnover |
— | 1.51 | 1.74 | 0.66 | 0.93 | 1.03 | 0.96 | 1.07 |
Operating CF/Net income |
— | 2.14 | 0.45 | 0.68 | 0.56 | (4.60) | (5.47) | (8.95) |
Capex/Depreciation |
— | 0.00 | 0.00 | (1.13) | (0.76) | (0.44) | (3.65) | (1.95) |
Interest Coverage |
— | 14.02 | 117.67 | (56.38) | (39.40) | 9.89 | (10.62) | (0.36) |
| — | 26.98% | 7.15% | (99.97%) | (662.46%) | (97.49%) | 152.29% | 24.38% | |
| — | 2.91% | 0.77% | (10.68%) | (17.00%) | 2.20% | 1.63% | 1.92% | |
ROIC |
— | 0.00% | 0.00% | (50.54%) | (20.54%) | 3.42% | (8.24%) | (0.45%) |
Return on Tangible Assets |
— | 7.69% | 1.55% | 163.66% | 71.32% | (17.43%) | (8.55%) | (14.31%) |
Average Days of Receivables |
— | 67.02 | 71.70 | 61.15 | 57.71 | 69.52 | 65.64 | 88.04 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 24.55% | 22.31% | 31.98% | 33.69% | 25.96% | 28.71% | 27.01% |
Intangible Assets out of Total Assets |
0.00 | 0.03 | 0.00 | 0.04 | 0.17 | 0.14 | 0.21 | 0.19 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 3.64% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | (0.49) | (0.49) | (0.51) | (1.71) | (1.83) | (1.50) | (7.00) |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
— | 0.00% | 0.00% | 0.00% | (62.24%) | (95.69%) | (81.10%) | (3,153.69%) |
Revenue per Share |
— | 7.73 | 8.91 | 7.80 | 10.09 | 10.98 | 9.93 | 10.72 |
Operating CF per Share |
— | 0.32 | 0.02 | (0.86) | (1.04) | (1.08) | (0.92) | (1.72) |
Capex per Share |
— | 0.00 | 0.00 | (0.16) | (0.18) | (0.13) | (1.34) | (0.73) |
Free Cash Flow per Share |
— | 0.32 | 0.02 | (1.02) | (1.22) | (1.21) | (2.26) | (2.45) |
Cash per Share |
— | 0.55 | 1.26 | 3.44 | 0.74 | 1.00 | 0.19 | 0.43 |
Shareholders Equity per Share |
— | (0.27) | 1.37 | 1.15 | (0.39) | (0.09) | 0.31 | 1.28 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.27) | 1.37 | 1.15 | (0.39) | (0.09) | 0.31 | 1.28 |
Free Cash Flow |
— | 1.28 | 0.07 | (4.11) | (5.94) | (5.90) | (11.03) | (12.52) |
Working Capital |
— | (12.91) | (8.13) | (5.31) | (16.51) | (9.85) | (12.79) | (9.74) |
Capital Expenditures |
— | (0.45) | (0.18) | (0.66) | (0.87) | (0.62) | (6.55) | (3.73) |
Net Current Asset Value |
— | (33.77) | (25.57) | (29.47) | (41.67) | (34.22) | (34.61) | (29.02) |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.14 | 0.07 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.02 | 0.02 | 0.26 | 0.30 | 0.43 | 0.56 | 0.67 |
Cash ROIC |
— | 4.74% | 0.22% | (11.29%) | (29.32%) | (25.24%) | (48.03%) | (59.26%) |
Accounts Receivable Turnover |
— | 4.88 | 5.62 | 5.11 | 7.55 | 5.96 | 5.13 | 5.00 |
Accounts Payable Turnover |
— | 18.56 | 22.46 | 31.15 | 26.62 | 21.03 | 28.99 | 10.42 |
Inventory Turnover |
— | 411.02 | 497.35 | 436.32 | 296.73 | 74.17 | 39.88 | 40.05 |
Average Days of Payables |
— | 20.97 | 15.18 | 8.40 | 21.10 | 15.00 | 9.56 | 61.16 |
Days of Inventory on Hand |
— | 0.95 | 0.68 | 1.00 | 1.71 | 8.24 | 9.72 | 9.14 |
Average Receivables |
— | 6.37 | 6.37 | 6.15 | 6.52 | 8.99 | 9.46 | 10.96 |
Average Payables |
— | 1.21 | 1.21 | 0.88 | 1.37 | 1.85 | 1.29 | 3.84 |
Average Inventory |
— | 0.05 | 0.05 | 0.06 | 0.12 | 0.52 | 0.94 | 1.00 |
Average Assets |
— | 20.61 | 20.61 | 47.46 | 53.03 | 52.15 | 50.29 | 51.01 |
Average Common Equity |
— | 2.23 | 2.23 | 5.07 | 1.36 | (1.18) | 0.54 | 4.03 |
Columns are period end dates